A federal judge has dismissed a suit claiming the law firm of Mazie, Slater, Katz & Freeman charged excessive fees in connection with a $358 million settlement of multidistrict litigation against makers of the blood pressure drug Olmesartan.

The suit claims Mazie Slater, of Roseland, New Jersey, and attorneys David Mazie and Adam Slater violated Rule 1:21‐7(i) of New Jersey’s Rules of Court. The rule states that in representation of several persons whose claims arose “out of the same transaction or set of facts or involve substantially identical liability issues,” the contingent fee shall be calculated on the basis of the aggregate of all recoveries, and should be charged to clients in proportion to the amount each recovers.